Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Glycoprotein 41 (gp41) Overview 8 Therapeutics Development 9 Glycoprotein 41 (gp41) - Products under Development by Stage of Development 9 Glycoprotein 41 (gp41) - Products under Development by Therapy Area 10 Glycoprotein 41 (gp41) - Products under Development by Indication 11 Glycoprotein 41 (gp41) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Glycoprotein 41 (gp41) - Products under Development by Companies 14 Glycoprotein 41 (gp41) - Products under Development by Universities/Institutes 16 Glycoprotein 41 (gp41) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 24 Amunix Operating Inc. 24 BioClonetics Immunotherapeutics, Inc. 25 Frontier Biotechnologies Co., Ltd 26 InnaVirVax SA 27 Laboratorios Del Dr. Esteve S.A. 28 Longevity Biotech, Inc 29 Mymetics Corporation 30 Navigen Pharmaceuticals, Inc. 31 Osel, Inc. 32 Pharis Biotec GmbH 33 Glycoprotein 41 (gp41) - Drug Profiles 34 Biologic for Infectious Disease - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 CLONE-3 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 CPT-31 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 DS-007 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Enfuvirtide-XTEN - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 FB-006M - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 HIV vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 HIV-1 vaccine - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 LBT-5001 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 MYMV-101 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 MYMV-201 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Recombinant Peptides for HIV-1 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Sifuvirtide - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 STOP-3S - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VAC-02 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 VAC-3S - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 VIR-353 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 VIR-576 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Glycoprotein 41 (gp41) - Dormant Projects 63 Glycoprotein 41 (gp41) - Featured News & Press Releases 64 Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 64 Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 64 Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 66 Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 67 Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 67 Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 68 Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 69 Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 69 Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 70 Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy 71 Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections 71 Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S 72 Sep 19, 2011: HIVACAT identifies candidate to HIV vaccine and initiates animal experimentation 73 Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections 74 May 26, 2011: Mymetics Realizes Successful Phase I Study With New HIV Vaccine MYM-V101 75 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78

List of Tables Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Amunix Operating Inc., H1 2016 24 Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016 25 Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016 26 Pipeline by InnaVirVax SA, H1 2016 27 Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 28 Pipeline by Longevity Biotech, Inc, H1 2016 29 Pipeline by Mymetics Corporation, H1 2016 30 Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 31 Pipeline by Osel, Inc., H1 2016 32 Pipeline by Pharis Biotec GmbH, H1 2016 33 Dormant Projects, H1 2016 63 List of Figures Number of Products under Development for, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

Amunix Operating Inc. BioClonetics Immunotherapeutics, Inc. Frontier Biotechnologies Co., Ltd InnaVirVax SA Laboratorios Del Dr. Esteve S.A. Longevity Biotech, Inc Mymetics Corporation Navigen Pharmaceuticals, Inc. Osel, Inc. Pharis Biotec GmbH